ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer

Withdrawn before enrolling · Phase 1

Conditions studied: Lip and Oral Cavity Cancer, Head and Neck Cancer, Oropharyngeal Cancer

In brief

RATIONALE: A specially modified virus called ONYX-015 may be able to kill tumor cells while leaving normal cells undamaged. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining ONYX-015 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of ONYX-015 combined with cisplatin and fluorouracil in treating patients who have advanced head and neck cancer.

Key facts

Study ID

NCT00006106

Run by

National Cancer Institute (NCI)

People needed

0

Starts

1999-07-01

Last updated by the study team

2013-07-10

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.